- In January 2020, Janssen Pharmaceuticals, Inc,. submitted a Type II Varian Application for SPRAVATO nasal spray to the European Medicines Agency. The proposal requests that nasal spray be used more widely as an acute, short-term therapy for depression symptoms. This would assist the business in generating revenue.
